Form DEFA14A ARROWHEAD PHARMACEUTICAL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program'
January 27, 2026 9:58 AM ESTMorgan Stanley analyst Michael E. Ulz reiterated an Equalweight rating and $81.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
The analyst comments "Overall, we are encouraged by the on track progress for the ARO-DIMER-PA program and Arrowhead has previously guided to... More
